New Patent for Adipose Stem Cells Issued to VetStem Biopharma
VetStem Biopharma issued patent that covers methods for extracting/preparing and using adipose tissue-derived stem cells for musculoskeletal injury in any mammal, including humans.
Leading regenerative veterinary medicine company, VetStem Biopharma, has been issued a major patent that covers methods for extracting and using adipose tissue-derived stem cells to treat or prevent inflammation at the site of musculoskeletal injury in any mammal, including humans. While this patent covers Canada specifically, VetStem has been issued similar patents that cover the United States as well as the EU.
The new patent adds to VetStem’s patent portfolio that covers methods of using regenerative cells from adipose tissue in humans and animals. CEO and VetStem founder, Dr. Bob Harman, believes these patents are an important way to strengthen the company’s intellectual property in the rapidly developing field of regenerative medicine.
As the first company to provide adipose derived stem cell services to veterinarians in the United States and Canada, VetStem has quickly developed the market. With over 13,000 animals treated, Dr. Harman believes it is crucial to take appropriate actions to protect the market they are developing and to optimize the value of the company. Dr. Harman stated, “We have invested heavily in patent protection of our technology and we have engaged appropriate counsel to work with companies interested in licensing our technology for commercial use.”
As stem cell therapy becomes more widely recognized and utilized in both veterinary and human medicine, VetStem strives to stay at the forefront of the field. They continue to explore non-standard uses for stem cells such as organ failure and immune-mediated diseases. The VetStem R&D team are also in the process of developing an off-the-shelf “donor-derived” stem cell product for arthritis in canines and additional products for use in feline and equine disease therapy. VetStem has three Investigational New Animal Drug applications filed with the FDA.